Karen L. Parkhill
Net Worth
Last updated:
What is Karen L. Parkhill net worth?
The estimated net worth of Ms. Karen L. Parkhill is at least $23,261,679 as of 2 Aug 2024. She owns shares worth $3,144,092 as insider, has earned $377,587 from insider trading and has received compensation worth at least $19,740,000 in Medtronic plc.
What is the salary of Karen L. Parkhill?
Ms. Karen L. Parkhill salary is $3,290,000 per year as EVice President, Chief Financial Officer, IT & Enterprise Excellence in Medtronic plc.
How old is Karen L. Parkhill?
Ms. Karen L. Parkhill is 60 years old, born in 1965.
What stocks does Karen L. Parkhill currently own?
As insider, Ms. Karen L. Parkhill owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Medtronic plc (MDT) | EVice President, Chief Financial Officer, IT & Enterprise Excellence | 34,946 | $89.97 | $3,144,092 |
What does Medtronic plc do?
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Karen L. Parkhill insider trading
Medtronic plc
Ms. Karen L. Parkhill has made 6 insider trades between 2019-2024, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 7,132 units of MDT stock on 2 Aug 2024. As of 2 Aug 2024 she still owns at least 34,946 units of MDT stock.